NO20060638L - Fremgangsmater for administrering av aripiprazol - Google Patents

Fremgangsmater for administrering av aripiprazol

Info

Publication number
NO20060638L
NO20060638L NO20060638A NO20060638A NO20060638L NO 20060638 L NO20060638 L NO 20060638L NO 20060638 A NO20060638 A NO 20060638A NO 20060638 A NO20060638 A NO 20060638A NO 20060638 L NO20060638 L NO 20060638L
Authority
NO
Norway
Prior art keywords
extended release
aripiprazole
methods
injection
administering
Prior art date
Application number
NO20060638A
Other languages
English (en)
Other versions
NO339816B1 (no
Inventor
Josiah Brown
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34116189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060638(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of NO20060638L publication Critical patent/NO20060638L/no
Publication of NO339816B1 publication Critical patent/NO339816B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den oppdagelse at en farmasøytisk blanding som omfatter aripiprazol og en bærer administrert som en bolusinjeksjon resulterte i en forlenget frigjøringsprofil i likhet med den oppnådd ved injeksjon av en polylaktid-ko-glykolid-mikrokule-formulering inneholdende virkestoffet, beskrives. Dette overraskende resultat tyder på at farmakologisk fordelaktige formuleringer med forlenget frigjøring kunne oppnås uten den kompleksitet og utgift som er forbundet med fremstillingen av mikrokuler.
NO20060638A 2003-08-06 2006-02-09 Injiserbar blanding for forlenget frigjøring av aripiprazol NO339816B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/635,221 US20050032811A1 (en) 2003-08-06 2003-08-06 Methods for administering aripiprazole
PCT/US2004/024345 WO2005016262A2 (en) 2003-08-06 2004-07-29 Methods for administering aripiprazole

Publications (2)

Publication Number Publication Date
NO20060638L true NO20060638L (no) 2006-04-26
NO339816B1 NO339816B1 (no) 2017-02-06

Family

ID=34116189

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060638A NO339816B1 (no) 2003-08-06 2006-02-09 Injiserbar blanding for forlenget frigjøring av aripiprazol

Country Status (22)

Country Link
US (9) US20050032811A1 (no)
EP (2) EP1660037B1 (no)
JP (3) JP5300194B2 (no)
CN (2) CN102133171A (no)
AT (1) ATE522200T1 (no)
AU (1) AU2004264886C1 (no)
CA (1) CA2534997C (no)
CY (1) CY1111874T1 (no)
DK (1) DK1660037T3 (no)
ES (1) ES2369893T3 (no)
HK (1) HK1091725A1 (no)
HR (1) HRP20110646T1 (no)
IL (1) IL173441A (no)
MX (1) MXPA06001350A (no)
NO (1) NO339816B1 (no)
NZ (1) NZ545037A (no)
PL (1) PL1660037T3 (no)
PT (1) PT1660037E (no)
SE (1) SE1660037T5 (no)
SI (1) SI1660037T1 (no)
WO (1) WO2005016262A2 (no)
ZA (1) ZA200601385B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
WO2007061896A1 (en) * 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
EP1880714A1 (en) 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US10632079B2 (en) * 2007-06-25 2020-04-28 Otsuka Pharmaceuticals Co., Ltd. Microspheres having core/shell structure
MY152789A (en) * 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
WO2010151711A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
EP3309151A1 (en) 2009-06-25 2018-04-18 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CA2814840C (en) 2010-10-18 2018-08-28 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
AR083884A1 (es) * 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) * 2010-12-14 2016-09-28 江苏豪森药业集团有限公司 一种持续释放的注射制剂及其制备方法和用途
HRP20240285T1 (hr) * 2011-03-18 2024-05-24 Alkermes Pharma Ireland Limited Farmaceutski pripravci koji sadrže sorbitan estere
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
ES2715562T3 (es) 2011-12-15 2019-06-04 Alkermes Pharma Ireland Ltd Profármacos de compuestos de amina secundaria
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
BR112016021535A8 (pt) * 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
CN105078898B (zh) * 2014-05-22 2018-08-28 上海现代药物制剂工程研究中心有限公司 阿立哌唑长效缓释微粒注射剂及其制备方法
CN106794251B (zh) * 2014-08-18 2020-12-29 阿尔科姆斯制药爱尔兰有限公司 阿立哌唑前体药物组合物
DK3185867T3 (da) 2014-08-25 2021-03-15 Alkermes Pharma Ireland Ltd Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
US20230310417A1 (en) 2020-03-30 2023-10-05 Cipla Limited Injectable aripiprazole formulation
CA3163321C (en) 2020-04-01 2023-12-19 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
CN115212174B (zh) * 2022-07-18 2024-02-20 辉粒药业(苏州)有限公司 一种载阿立哌唑长效缓释微球及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5832899A (ja) 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US7179486B1 (en) * 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2001293048A1 (en) * 2000-09-26 2002-04-08 The Johns Hopkins University Antiviral compositions and methods of use
DE10048868A1 (de) * 2000-10-02 2002-04-11 Basf Ag Verfahren und Vorrichtung zur Einmischung von Zusatzstoffen während der Konditionierung von Tierfutter
JP2002191256A (ja) 2000-12-26 2002-07-09 Yoshikatsu Nakajima 水 槽
CN1813699B (zh) 2001-06-14 2012-04-18 大塚制药株式会社 药物组合物
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren

Also Published As

Publication number Publication date
EP1660037A2 (en) 2006-05-31
AU2004264886C1 (en) 2021-06-03
ZA200601385B (en) 2007-02-28
US8759351B2 (en) 2014-06-24
PL1660037T3 (pl) 2012-03-30
CA2534997A1 (en) 2005-02-24
US20230218506A1 (en) 2023-07-13
JP5300194B2 (ja) 2013-09-25
US20190231679A1 (en) 2019-08-01
SI1660037T1 (sl) 2012-05-31
DK1660037T3 (da) 2011-12-12
NZ545037A (en) 2008-10-31
CN102133171A (zh) 2011-07-27
CA2534997C (en) 2011-11-01
HRP20110646T1 (hr) 2011-12-31
EP1660037B1 (en) 2011-08-31
CY1111874T1 (el) 2015-11-04
US20050032811A1 (en) 2005-02-10
AU2004264886B2 (en) 2007-06-07
IL173441A0 (en) 2006-06-11
MXPA06001350A (es) 2006-08-23
JP2010248258A (ja) 2010-11-04
US20120289516A1 (en) 2012-11-15
ATE522200T1 (de) 2011-09-15
IL173441A (en) 2013-04-30
AU2004264886A1 (en) 2005-02-24
JP5764634B2 (ja) 2015-08-19
PT1660037E (pt) 2011-10-24
US20210346282A1 (en) 2021-11-11
JP5453194B2 (ja) 2014-03-26
US20130090343A1 (en) 2013-04-11
EP2340810A1 (en) 2011-07-06
CN1845721A (zh) 2006-10-11
HK1091725A1 (en) 2007-01-26
NO339816B1 (no) 2017-02-06
ES2369893T3 (es) 2011-12-07
US20180169005A1 (en) 2018-06-21
JP2007501236A (ja) 2007-01-25
WO2005016262A2 (en) 2005-02-24
US20140275109A1 (en) 2014-09-18
US8338428B2 (en) 2012-12-25
SE1660037T5 (no) 2015-09-15
WO2005016262A3 (en) 2005-09-09
US20090143403A1 (en) 2009-06-04
US8338427B2 (en) 2012-12-25
EP1660037A4 (en) 2008-09-24
JP2014001250A (ja) 2014-01-09

Similar Documents

Publication Publication Date Title
NO20060638L (no) Fremgangsmater for administrering av aripiprazol
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
MX2007005644A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa.
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
BRPI0620063B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
MY151468A (en) Controlled release solid preparation
WO2010015665A3 (en) Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
NZ594618A (en) Transdermal pharmaceutical preparations
IL187678A0 (en) Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
WO2005030132A3 (en) Therapeutic regimens for administering drug combinations
ATE334658T1 (de) Arzneimittel zur verabreichung an schleimhäute
SE0203817D0 (sv) New composition
BR0315231A (pt) Compostos com base em glicose com afinidade para p-seletina
EA200701010A1 (ru) Препарат гепирона с высокой дозировкой и длительным высвобождением
SG146671A1 (en) Therapeutic regimens for administering drug combinations

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: OTSUKA PHARMACEUTICAL CO., JP